# Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure

> **NCT02862600** · PHASE2 · TERMINATED · sponsor: **Heart Metabolics Limited** · enrollment: 35 (actual)

## Conditions studied

- Cardiomyopathy, Hypertrophic
- Cardiomyopathy, Hypertrophic, Familial

## Interventions

- **DRUG:** Perhexiline
- **DEVICE:** Use of bioanalytical assay to monitor plasma levels of perhexiline

## Key facts

- **NCT ID:** NCT02862600
- **Lead sponsor:** Heart Metabolics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-08-01
- **Primary completion:** 2017-04-28
- **Final completion:** 2017-05-22
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** Lack of Efficacy
- **Last updated:** 2017-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02862600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02862600, "Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT02862600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*